Pulmonary Nodule denials in California external review

In the California DMHC record, independent physician reviewers decided 13 published external-review cases involving pulmonary noduleand overturned the plan’s denial in 23.1%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.

California DMHC decisions
13
2007–2024
Overturned
23.1%
3 denials reversed

What the insurer actually argued

Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
Reason givenDecisionsOverturned
Medical Necessity
The plan said the care wasn’t medically necessary. The most common fight, and the most winnable.
9
22.2%
Experimental/Investigational
The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument.
4
25%
Typical time to a decision
13 days
Most land between 6 and 17 days
Handled as urgent
46.2%
Expedited when a delay would cause harm

What the reviewers wrote

Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.

Where the denial was overturned

Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for electromagnetic navigational bronchoscopy (ENB)for treatment of the enrollee with history of pulmonary nodules. Findings: The physician reviewer found that transthoracic needle biopsy (TTNB) has a better diagnostic rate, there is a higher risk for pneumothorax, greater than 10% when compared to 3% to ENB. The primary disadvantage of TTNB is that a pneumothorax develops in 11% to 24% of patients and 5% to 14% require insertion of a chest tube. The National Comprehensive Cancer Network (NCCN) clinical practice guidelines for non small-cell lung cancer state that the strategy for diagnosing lung cancer should be individualized and the least invasive biopsy with the highest diagnostic yield is preferred as the initial diagnostic study.
Experimental/Investigational · 2018 · IMR EI18-27812
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for a computed tomography (CT) scan of the chest. The records indicate that the patient has multiple unclear pulmonary nodules found incidentally on a CT scan of the cervical spine, of unclear etiology. Given the findings of the patient’s cervical spine CT scan, dedicated imaging of the patient’s chest is indicated and the next best step for workup of the unclear nodules. Identification of the size, characteristics, and possible additional lesions is required prior to the determination of interventions or diagnostic evaluation. As such, a dedicated CT scan of the chest is paramount to determine the course of action required for diagnosis and potential management of the patient’s condition. Without further imaging, the patient is at risk of receiving inadequate care.
Medical Necessity · 2024 · IMR MN24-42360

Where the denial was upheld

Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for the positron emission tomography/computed tomography (PET/CT) scan. Findings: Three physician reviewers found that in this patient’s case, the guidelines do not support the efficacy of the PET/CT scan at issue. This patient presented with an incidental finding of a 4 mm pulmonary nodule, noted on a CT scan. The Society of Thoracic Imaging and Diagnosis, otherwise known as the Fleischner Society, is a well-known organization that has established guidelines for the evaluation of incidentally detected pulmonary nodules. These evidence based guidelines were revised in 2017 and are widely used throughout radiology. For incidentally detected nodules that are greater than 8 mm, the Fleischner Society guidelines call for either a follow up CT scan in three months, and/or a PET/CT, and/or a biopsy.
Experimental/Investigational · 2017 · IMR EI17-25620
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for a positron emission tomography (PET) scan for evaluation of the enrollee’s lung nodule. Findings: Two of the three physician reviewers found that this patient presented with an incidental finding of a pulmonary nodule. He was then evaluated appropriately, first with a routine CT scan to confirm the presence of the nodule. At that point, a decision was needed concerning how to further evaluate the nodule. The Society of Thoracic Imaging and Diagnosis, otherwise known as the Fleischner Society, is a well-known organization that has established guidelines for the evaluation of incidentally detected pulmonary nodules.
Experimental/Investigational · 2017 · IMR EI17-25067

Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.

How to use this in your appeal

These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving pulmonary nodule, then check the rights and deadlines that apply to your plan.

SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY

Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.

Fighting a denial for pulmonary nodule? Use the California record to prepare.

Explain my denial — freeStart my appeal · $9